A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.

Serina Therapeutics, based at the HudsonAlpha Institute of Biotechnology campus, announced in a press release this week that it will start clinical trials in the second half of this year. The funding comes from UK-based investor JuvVentures.

The company says it is leveraging its own drug-delivery technology to make an existing Parkinson’s medication, apomorphine, more effective and easier to use. The proposed treatment combines the company’s technology with a wearable device from Enable Injections, for ease of administration. The system aims to deliver apomorphine in a way that could make it last longer in the body.